Valion Bio Announces $1.5M Series B Financing; CEO Terminated

What Happened

• Valion Bio, Inc. filed an 8-K on August 17, 2026 announcing a Letter Agreement under its Series B Preferred Purchase Agreement to issue 1,500 shares of Series B Non‑Voting Convertible Preferred Stock at $1,000 per share and related Series B warrants for an aggregate $1,500,000 (closing expected on or about August 17, 2026). The securities were issued under Section 4(a)(2)/Rule 506(b) exemptions.
• The company also agreed (as of August 17, 2026) to enter a Royalty Agreement with 3i, LP and other purchasers under which they will receive cash payments equal to 5% of gross revenue of Velocity Bioworks, Inc. (a wholly owned subsidiary) from third parties for 10 years.
• Corporate changes: effective August 16, 2026 Michael K. Handley was terminated as CEO; Lisa Wolf (currently CFO) was appointed Chief Operating Officer, effective immediately and continues as CFO.

Key Details

• Immediate financing: $1,500,000 via issuance of 1,500 Series B preferred shares at $1,000/share plus associated warrants (per Series B Purchase Agreement terms).
• Royalty commitment: 5% of Velocity Bioworks’ gross third‑party revenue for 10 years payable to 3i and other Series C purchasers (aggregate).
• Leadership changes: CEO Michael K. Handley terminated (effective Aug 16, 2026); Lisa Wolf named COO and remains CFO. No changes to Ms. Wolf’s July 5, 2025 employment agreement were reported.
• Corporate action approved: On Aug 14, 2026 stockholders approved Board authority to implement a reverse stock split between 1‑for‑5 and 1‑for‑50 within 12 months (preliminary vote: 1,243,030 for; 697,127 against).

Why It Matters

• The $1.5M closing provides near‑term liquidity but is part of a larger, unsettled financing plan—additional tranches are being negotiated with no definitive agreements yet.
• The 10‑year royalty (5% of gross revenue from Velocity Bioworks) creates a long‑term cash obligation that will reduce future subsidiary revenue available to the company.
• Leadership changes (CEO departure and dual role for Lisa Wolf as COO/CFO) and the approved reverse split authorization are significant governance events that can affect operations, investor perception, and the company’s capital structure. Investors should watch for further financing tranches, any interim CEO appointment, and updates on the royalty agreement’s implementation.